New antibody EPI-326 enters first human trials for tough cancers
NCT ID NCT07462377
First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times
Summary
This early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung or head & neck cancers that have specific EGFR mutations. The drug is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EPI-326 (a bispecific antibody given by IV infusion)
- What this could lead to
- If it works, this could point toward a new treatment option for certain lung and head & neck cancers that have not responded to other therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 110 people, focused on safety and dosing. It may not show strong anti-tumor effects, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Astera Cancer Care
RECRUITINGEast Brunswick, New Jersey, 08816, United States
Contact Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
START Los Angeles
RECRUITINGLos Angeles, California, 90025, United States
Contact Email: •••••@•••••
-
START New York Long Island
RECRUITINGLake Success, New York, 11042, United States
Contact Email: •••••@•••••
-
Sarah Cannon and HCA Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics (START)
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?